Board committee recommends support for dozen‑plus pharmacy bills; signals caution on compounding and biosimilars

The California State Board of Pharmacy Legislation & Regulation Committee on April 29 voted to recommend positions on a broad slate of measures affecting pharmacy practice, drug pricing and patient access.

Chair Jesse Crowley opened the committee by outlining the board’s consumer‑protection mission and then guided members through staff summaries of each bill. The committee recommended support for measures including AB 910 (PBM transparency), AB 957 (ban on tobacco sales in pharmacies), AB 1773 (PBM public disclosures), AB 2565 (DHCS guidance to ensure pharmacist services coverage), AB 2571 (reimbursement parity for advanced pharmacist practitioners), and SB 1199 (counting manufacturer assistance toward out‑of‑pocket maximums). “These measures are largely about preserving patient access and ensuring transparency,” Crowley said when introducing several items.

Why it matters: The committee’s recommendations are advisory to the full board but signal how the board intends to weigh public‑policy tradeoffs this legislative session. Several bills the committee backed would increase transparency of prescription pricing and limit insurer or PBM practices that can hinder timely access to therapies.

How the committee voted: For example, on AB 910 the committee adopted staff’s recommendation to support the bill; Maria Serpa moved the recommendation and Nicole Tibo seconded, and the motion passed on a roll call (Janette Dong, Maria Serpa, Nicole Tibo and Chair Jesse Crowley all voted yes). Similar roll‑call approvals were recorded for AB 957, AB 1773, AB 2565, AB 2571, SB 915, SB 964 and SB 1199. A list of motions and recorded outcomes follows below.

Tensions and technical fixes: Committee members and staff repeatedly urged technical amendments where bill language could create regulatory gaps or implementation confusion. For AB 1811 (shortage‑area definitions), staff recommended clarifying that pharmacy settings are included; for SB 1347 (stock emergency albuterol inhalers) staff recommended mirroring an education code authority in pharmacy law so pharmacies clearly understand their ability to furnish inhalers to schools and child‑care programs.

Quotes from members and commenters: Members regularly deferred to staff attorneys and subject experts for technical clarifications. In debate over pharmacist reimbursement, Sean Kim of the California Pharmacists Association urged the committee to consider on‑the‑ground enrollment and plan‑contracting barriers that prevent pharmacists from being paid for covered services. “There’s a lot of fragmented enrollment and no financial sustainability,” Kim said in public comment. Pharmacy technicians and practicing pharmacists also offered views during public comment periods.

Votes at a glance (selected items and committee recommendations): - AB 910 (PBM transparency) — Committee recommendation: Support — Vote: Janette Dong yes; Maria Serpa yes; Nicole Tibo yes; Chair Jesse Crowley yes. (SEG 207–271) - AB 957 (Prohibit cigarette/tobacco sales at pharmacies) — Committee recommendation: Support — Motion passed by roll call after public comment from a pharmacy technician. (SEG 272–350) - AB 1558 (Uniform Emergency Volunteer Health Practitioners Act) — Committee recommendation: Support if amended — Motion passed. (SEG 463–535) - AB 1773 (DMHC PBM public website) — Committee recommendation: Support — Motion passed. (SEG 632–673) - AB 1979 (AI and clinical decision support) — Committee recommendation: Support if amended (extend explicit coverage to pharmacist practice sites) — Motion passed. (SEG 1165–1310) - AB 2565 (DHCS guidance on pharmacist services coverage) — Committee recommendation: Support — Motion passed after public comment describing coverage and enrollment barriers. (SEG 2384–2499) - AB 2571 (Reimbursement parity for advanced pharmacist practitioners) — Committee recommendation: Support — Motion passed. (SEG 2501–2547) - SB 915 (Limits on immigration enforcement presence during care) — Committee recommendation: Support — Motion passed. (SEG 2548–2625) - SB 1199 (Count manufacturer assistance toward out‑of‑pocket max) — Committee recommendation: Support — Motion passed. (SEG 2929–3000) - SB 1347 (School/childcare emergency albuterol stock) — Committee recommendation: Support (technical amendments suggested) — Motion passed. (SEG 3001–3061)

What the committee did not finalize: The committee reserved a watch or no‑position posture on several measures that prompted substantive debate or required more technical work. Notably, AB 1990 (compounding of GLP‑1 and related products) drew extensive public comment and divided views among stakeholders; staff and members expressed significant concerns about scope, enforcement provisions and potential duplication with USP and federal standards, and the committee did not take a final support position (see separate coverage of the AB 1990 debate).

Next steps: Committee recommendations will be forwarded to the full California State Board of Pharmacy. The committee’s next meeting is scheduled for June 11, 2026, where members indicated they expect to revisit some watch items and technical amendment proposals.

Ending: The committee adjourned after a regulations update and a reminder about the full board meeting later in the day.

Provenance: Primary evidence for the roundup is drawn from staff presentations and roll‑call votes captured in the transcript segments listed in the committee record (topic introductions through topic finishes for items above).